Near-infrared spectral tomography for predicting residual cancer burden during early stage neoadjuvant chemotherapy for breast cancer

CONCLUSION: NIRST holds promise as a potential clinical tool that can be seamlessly integrated into existing clinical workflow within the infusion suite. By providing early assessment of RCB, NIRST has potential to improve breast cancer patient management strategies.PMID:37733788 | DOI:10.1158/1078-0432.CCR-23-1593

Source: Clinical Cancer Research - September 21, 2023 Category: Cancer & Oncology Authors: Xu Cao Kristen E Muller Mary D Chamberlin Jiang Gui Peter A Kaufman Gary N Schwartz Roberta M DiFlorio-Alexander Brian W Pogue Keith D Paulsen Shudong Jiang Source Type: research